Login to Your Account



Phase I Clinical Trials Update: October 2011


Monday, November 14, 2011

Company  (Location)

Product

Description

Indication

Status (Date)#


AUTOIMMUNE

Allozyne Inc. (Seattle)

AZ01

A pegylated interferon beta 1-b drug

Relapsing/remitting multiple sclerosis

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription